Table-3.
Temporal Trends in Antithrombotic Use in the Study Cohort
| Leak= 0 mm (N=37,696) | Leak= >0–5 mm (N=13,258) | Leak >5 mm (N= 379) | p-value | |
|---|---|---|---|---|
| Discharge medication | ||||
| Aspirin | 13171 (34.9%) | 4906 (37.0%) | 154 (40.6%) | <.0001 |
| Warfarin | 16894 (44.8%) | 6127 (46.2%) | 188 (49.6%) | 0.005 |
| DOAC | 17966 (47.7%) | 6148 (46.4%) | 160 (42.2%) | 0.005 |
| P2Y12 inhibitor | 4916 (13.0%) | 1636 (12.3%) | 48 (12.7%) | 0.115 |
| Bridging anticoagulant therapy | 357 (0.9%) | 127 (1.0%) | 7 (1.8%) | 0.201 |
| None/Other? | 1805 (4.8%) | 626 (4.7%) | 22 (5.8%) | 0.613 |
| 45-day medication | ||||
| Aspirin | 12117 (32.1%) | 4581 (34.6%) | 131 (34.6%) | <.0001 |
| Warfarin | 12206 (32.4%) | 4556 (34.4%) | 170 (44.9%) | <.0001 |
| DOAC | 13383 (35.5%) | 4700 (35.5%) | 142 (37.5%) | 0.721 |
| P2Y12 inhibitor | 11041 (29.3%) | 3592 (27.1%) | 61 (16.1%) | <.0001 |
| Bridging anticoagulant therapy | 133 (0.4%) | 44 (0.3%) | 1 (0.3%) | 0.905 |
| None | 7913 (21.0%) | 2458 (18.5%) | 42 (11.1%) | <.0001 |
| 180-day medications | ||||
| Aspirin | 8526 (22.6%) | 3416 (25.8%) | 99 (26.1%) | <.0001 |
| Warfarin | 539 (1.4%) | 315 (2.4%) | 65 (17.2%) | <.0001 |
| DOAC | 1368 (3.6%) | 653 (4.9%) | 83 (21.9%) | <.0001 |
| P2Y12 inhibitor | 17557 (46.6%) | 6268 (47.3%) | 94 (24.8%) | <.0001 |
| Bridging anticoagulant therapy | 89 (0.2%) | 29 (0.2%) | 1 (0.3%) | 0.930 |
| None | 27605 (73.2%) | 9081 (68.5%) | 166 (43.8%) | <.0001 |
| 1-year medications | ||||
| Aspirin | 4923 (13.1%) | 1932 (14.6%) | 56 (14.8%) | <.0001 |
| Warfarin | 266 (0.7%) | 132 (1.0%) | 13 (3.4%) | <.0001 |
| DOAC | 847 (2.2%) | 380 (2.9%) | 41 (10.8%) | <.0001 |
| P2Y12 inhibitor | 3946 (10.5%) | 1511 (11.4%) | 55 (14.5%) | 0.001 |
| Bridging anticoagulant therapy | 61 (0.2%) | 32 (0.2%) | 0 (0.0%) | 0.127 |
| None | 31785 (84.3%) | 10874 (82.0%) | 275 (72.6%) | <.0001 |
DOAC; direct oral anticoagulant